ClinicalTrials.gg
RecruitingNCT05270200Updated Jul 7, 2026

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

A Phase 1/2 interventional study of Azacitidine and Chidamide in Leukemia, Myeloid, Acute, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Zhujiang Hospital · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing tucidinostat in Leukemia, Myeloid, Acute — 11 open to participants now, 11 under way, 1 of them phase 3. tucidinostat · Leukemia, Myeloid, Acute.

Planned enrollment
12th of 14
40 · median 99
Started
2022
with 1 other
Phase 1/2
2 of 14
2 open now
Primary completion
2027-12
later than 7 of 10 live
Registered
1st of 14
by date
Lead sponsor
1 of 14
Zhujiang Hospital

Among the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute, this one is the 12th largest by planned enrollment, is one of 2 that started in 2022, is one of 2 in phase 1/2, reaches primary completion later than 7 of the 10 other live ones, and was the 1st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

11 of the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tucidinostat in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.

Read the detailed description

The Study Drug:

Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better.

Chidamide exhibits potent inhibitory effect on cell viability of MDS and AML cells, and the possible mechanism may lie in the downregulation of JAK2/STAT3 signaling through SOCS3 upregulation.

Study Group: If you are found to be eligible to take part in this study,you will receive azacitidine and chidamide.

Study Drug Administration:

You will recieve six courses of azacitidine through a needle under your skin on Days 1-3.Each course is 28 days long.At the same time you will recieve oral chidamide per day for no more than 2 years.

The treatment will start after 30 days post-transplantation and your neutrophil count is of 1.5 × 10⁹ cells per L or higher and non-transfused platelets is of 80 × 10⁹ per L or higher.

The treatment would stop if neutrophil count is less than 0.5 × 10⁹ cells per L or platelets is less than 50 × 10⁹ per L.And it would also stop when grade 3/4 non-hematological adverse events happened.

Study Visit:

You may come back for study visits every month in a year when the treatment start.

Blood and urine will be drawn for routine tests every month. At 1,2,3,4,5,6,9 and 12 months,You will have a bone marrow aspiration to check the status of the disease.

You will have a electrocardiiogram test every 3 months to check the heart function.

Length of Study:

You will be on study treatment for up to 1 year.You will be taken off study early if you experience intolerable side effects or the disease gets worse.

End-of-Treatment Visit:

If you complete the planned treatment with azacitidine and chidamide, you will have an end-of-treatment visit:

Blood and urine will be drawn for routine tests. You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function.

This is an investigational study. Azacitidine and chidamide are FDA approved and are commercially available for the treatment of acute leukemia.

03

Conditions studied

  • Leukemia, Myeloid, Acute

Keywords

  • Acute myelogenous leukemia
  • Allogenetic stem cell transplant
  • Maintenance therapy
  • Azacitidine
  • Chidamide
  • High-risk AML
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age 18 to 60 years old,both male and female
  • 2.Be able to understand and sign
  • 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic
  • 4.Patients have AML with poor genetic abnormalities,primary AML,relapsed AML or secondary AML
  • 5.Patients with an performance status 0,1,2 or 3
  • 6.Expected survival time ≥ 3 months
  • 7.Non-hematological toxicity related to transplantation does not exceed Grade 2
  • 8.Laboratory indicators meet the following standards:

    1. 7 days before the first day of the first course of treatment, , and AST were all less than 3 times the .
    2. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the are greater than 1.5×10/L and without G-CSF treatment.
    3. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, count greater than 80×10/L and without platelet transfusion.
    4. Serum rate is greater than 30ml/min.

Exclusion criteria

Exclusion Criteria:

  • 1.Uncontrollable active infection
  • 2.Patients with active or C or infection before enrollment
  • 3.Have a grade III-IV
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Azacitidine combined with Chidamide

    Patients will recieve six courses of azacitidine 50mg/m2 through a needle under your skin on Days 1-3.Each course is 28 days long.At the same time patients will recieve oral chidamide 5mg per day for no more than 2 years.

    Drug: Azacitidine · Drug: Chidamide

Interventions

  • Patients will recieve six courses of azacitidine 50mg/m2 through a needle under skin on Days 1-3.Each course is 28 days long.

    Also known as: 5-Azacitidine, 5-aza, Vidaza, 5-AZC

  • Patients will recieve oral chidamide 5mg per day for no more than 2 years.

    Also known as: Epidaza

06

What researchers measure

Primary outcomes

  1. Number of Paticipants With Adverse Events as a Measure of Safety

    Safety were measured with respect to: 1. Safety measurements 2. Incidence of adverse events

    Time frame: From the day of stem cell transplantation to one year after stem cell transplantation

  2. One year cumulative incidence of relapse

    Leukemia relapse base on morphoogy criterion

    Time frame: From the day of stem cell transplantation to one year after stem cell transplantation

Secondary outcomes

  1. Relapes-free Survival(RFS)

    The time that a participant survives without relapes of the disease

    Time frame: From the day of stem cell transplantation to one year after stem cell transplantation

  2. Overall survival(OS)

    The time that a participant survives without death

    Time frame: From the day of stem cell transplantation to one year after stem cell transplantation

  3. The cumulative Incidence rate of GVHD

    acute GVHD and chronic GVHD diagnosis based on MIH criterion

    Time frame: From the day of stem cell transplantation to one year after stem cell transplantation

Other outcomes

  1. Single-cell sequencing

    Single-cell sequencing was used to explore the potential mechanism of AZA combined with sidarbenamide to prevent recurrence after transplantation in patients with AML

    Time frame: Before the maintenance therapy and before the 7 cycles of maintenance

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We will share our data within 6 months after the end of the trial. You can ask us for data or obtain it on the Clinical Trial Management Public Platform of clinical trial.

Supporting information: Study protocol

Time frame: The data will be available and permanently disclosed within 6 months after the trial.

Access criteria: You can log in to the website for data access or contact us for data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2027, 70 months after the start.

Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's planned 70 months is close to that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Mar 8, 2022
StartActual
Feb 1, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05270200
Lead sponsor
Zhujiang Hospital
Responsible party
Sponsor
First posted
Mar 8, 2022
Start date
Feb 1, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Rui Huang, Doctor
Contact
Rachelchn@163.com
+8615918528317
Yunqing Wang, Bachelor
Contact
Wangyun7q@163.com
+8618585509970
Rui Huang, Doctor
principal investigator · Zhujiang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion